Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemiaLeukemia, Published online: 30 August 2017; doi:10.1038/leu.2017.276

Source: Leukemia - August 30, 2017 Category: Hematology Authors: S Degryse C E de Bock S Demeyer I Govaerts S Bornschein D Verbeke K Jacobs S Binos D A Skerrett-Byrne H C Murray N M Verrills P Van Vlierberghe J Cools M D Dun Source Type: research